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Summary
OBJECTIVE: Vitamin D (D3) status is reported to correlate
negatively with insulin production and insulin sensitivity in
patients with type 2 diabetes mellitus (T2DM). However,
few placebo-controlled intervention data are available. We
aimed to assess the effect of large doses of parenteral D3
on glycosylated haemoglobin (HbA1c) and estimates of in-
sulin action (homeostasis model assessment insulin resist-
ance: HOMA-IR) in patients with stable T2DM.
MATERIALS AND METHODS: We performed a pro-
spective, randomised, double-blind, placebo-controlled pi-
lot study at a single university care setting in Switzerland.
Fifty-five patients of both genders with T2DM of more
than 10 years were enrolled and randomised to either
300,000 IU D3 or placebo, intramuscularly. The primary
endpoint was the intergroup difference in HbA1c levels. Se-
condary endpoints were: changes in insulin sensitivity, al-
buminuria, calcium/phosphate metabolism, activity of the
renin-aldosterone axis and changes in 24-hour ambulatory
blood pressure values.
RESULTS: After 6 months of D3 supply, there was a signi-
ficant intergroup difference in the change in HbA1c levels
(relative change [mean ± standard deviation] +2.9% ±
1.5% in the D3 group vs +6.9% ± 2.1% the in placebo
group, p = 0.041) as HOMA-IR decreased by 12.8% ±
Abbreviations
CHD = coronary heart disease
FGF-23: fibroblast growth factor 23
HBA1c: glycosylated haemoglobin
HOMA: homeostasis model assessment
HOMA-IR: homeostasis model assessment insulin resistance
hsCRP: high-sensitivity C-reactive protein
PTH: parathyroid hormone
T2DM: type 2 diabetes mellitus
T1DM: type 1 diabetes mellitus
5.6% in the D3 group and increased by 10% ± 5.4% in the
placebo group (intergroup difference, p = 0.032). Twenty-
four-hour urinary albumin excretion decreased in the D3
group from 200 ± 41 to 126 ± 39, p = 0.021). There was
no significant intergroup difference for the other secondary
endpoints.
CONCLUSIONS: D3 improved insulin sensitivity (based
on HOMA-IR) and affected the course of HbA1c positively
compared with placebo in patients with T2DM.
Clinical trial registration number at ClinicalTrials.gov:
NCT01585051
Key words: Diabetes mellitus; vitamin D; FGF-23; insulin
sensitivity
Introduction
Epidemiological and observational evidence suggests that
vitamin D (D3) supply inversely correlates with the risk for
T2DM and, once diabetic, serum 25(OH)-D3 levels correl-
ate inversely with impaired glucose tolerance [1, 2]. Since
cardiovascular events are greatly increased in T2DM, it has
been suggested that D3 status measured as serum 25(OH)-
D3 levels might be a modifiable risk factor for cardiovascu-
lar events in T2DM patients, as well as in the general popu-
lation [1, 2]. D3 is required for and improves the production
of insulin, and is also implicated in the mechanism of in-
sulin action [3, 4]. However, in both nondiabetic and dia-
betic patients, the clinical associations of D3 with insulin
resistance and beta-cell function are inconsistent [2, 5, 6],
and reported intervention studies employing D3 either as
25(OH)-D3 (e.g., cholecalciferol) or as 1,25(OH)2-D3 (e.g.,
calcitriol) have yielded conflicting results that are difficult
to interpret owing to lack of placebo control [7, 8].
Supplementation of D3 and calcium (400 IU D3 and 1000
mg calcium daily) did not reduce the risk of developing
diabetes in the Women’ s Health Study over 7 years of
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follow-up [7] and supplementation of D3 in normal subjects
(20,000 IU D3 orally twice weekly for 6 months) did not
affect insulin secretion nor sensitivity [8], whereas supple-
menting 700 IU D3 daily over 3 years was found to atten-
uate the increases in glycaemia and insulin resistance in
elderly subjects with impaired fasting glucose at baseline
[9]. In a short-term study (4 weeks) in nondiabetic subjects
with D3 deficiency (25(OH)-D3 <25 nmol/l) two oral doses
of D3 (100,000 IU D3 2 weeks apart) had no significant
effect on serum glucose, insulin concentration and insulin
sensitivity assessed with an oral glucose tolerance test [10].
However, in a study of subjects at risk for T2DM, oral sup-
plementation of D3 (2,000 IU D3 daily for 4 months) was
shown to improve beta-cell function, but not insulin sensit-
ivity [11].
Results from randomised controlled trials that evaluated
the specific effects of 25(OH)-D3 or 1,25(OH)2-D3
(without also adding calcium to D3) on glucose and insulin
homeostasis in T2DM patients have been conflicting [2,
12–20]. A recently published systematic review examining
the effect of vitamin D supplementation in 15 newer pub-
lished studies [21] again found discrepancies in outcomes,
which may be due to heterogeneous study populations
(number of patients included, stage of diabetes, gender,
age, oral or insulin treatment) or to heterogeneous interven-
tions (oral, parenteral, dose, duration).
In view of the suggestive but inconclusive evidence for a
clinically important effect of exogenous D3 supplementa-
tion on glucose and insulin homeostasis in both normal and
diabetic subjects and as few placebo-controlled interven-
tion data are available, we wished to assess insulin sens-
itivity to large doses of D3 in a double-blinded, random-
ised, placebo-controlled trial in stable T2DM patients. In
addition, in view of the lack of information on responses of
calcium/phosphate metabolism, calci-/phosphotropic hor-
mones and 24-hour ambulatory blood pressures to large
doses of D3 in T2DM patients, this study also explored
these data.
Methods
Study design and treatment protocol
This prospective, randomised, double-blind, placebo-con-
trolled pilot study was performed at a single university care
setting in Switzerland. The study was approved by the loc-
al internal review board (EKBB, University of Basel), the
study subjects gave written, informed consent and were
paid CHF 50.00 for each office visit. Patients were re-
cruited from the ambulatory care facilities (diabetology
and cardiology) of the hospital. Randomisation was per-
formed by a pharmacist using a computer program. He
provided the randomisation codes and vials containing D3
or 0.9% NaCl. A nurse not involved in the study admin-
istered the injections, either D3 (cholecalciferol, 300,000
IU, 1 ml intramuscularly, vitamin D3 Streuli Inc., Switzer-
land), or placebo (0.9% NaCl, 1 ml intramuscularly) in a
blinded way. After 3 months, all patients received a blinded
repeat injection which contained either 0.9% NaCl 0.5 ml
(placebo arm or for D3 replete patients in the D3 arm) or D3
150,000 IU, 0.5 ml (only patients in the D3 arm when ser-
um 25(OH)-D3 levels were below 80 nmol/l in the D3 arm
and hypercalcaemia of any degree and hypercalciuria [≥8
mmol/24 hours] remained absent). An independent (non-
study) physician evaluated the serum 25(OH)-D3 and cal-
cium results and allocated D3/NaCl administration via the
hospital pharmacist who had provided the randomisation
code.
Inclusion criteria
Men and nonpregnant women aged ≥18 years, with T2DM,
living independently at home with stable blood glucose
control for the past 2 months (less than 2 hypoglycaemic
episodes in the past 2 months, unchanged doses of anti-
hyperglycaemic agents in the last 3 months and stable glyc-
osylated haemoglobin [HbA1c] levels for the past 6 months
[variation by less than ±0.7%]). Blood pressure was to be
stable below 145/85 mm Hg during the past 2 months un-
der a fixed current regimen of blood pressure medications
(if any) and/or potassium supplements (if any). Both dia-
betic and blood pressure therapies had to be judged as un-
likely to require change in the subsequent 6 months by the
referring diabetologist and cardiologist. It was prespecified
that if changes in these medication regimens were needed
during the study, these subjects would be regarded as drop-
outs and not included into the analysis.
Exclusion criteria
– Patients with type 1 diabetes mellitus (T1DM) or
insulin-requiring diabetes of undetermined type
– Patients on haemodialysis, with hyperparathyroidism or
active cancer disease
– Patients with known metabolic bone disease
– Laboratory evidence of kidney (estimated glomerular
filtration rate <60 ml/min) or liver disease
– Dietary calcium intake exceeding 1,500 mg/d
(estimated from diet history)
– 25(OH)-D3 levels at baseline ≥70 nmol/l
– Hypercalciuria (>8 mmol/24 hours, measured by means
of 24-hour urine collections)
– Hypo- and hypercalcaemia and hypo- and
hyperphosphatemia of any cause
– Drugs that affect D3 metabolism (e.g., antiepileptic
drugs, calcimimetics, 1-34 PTH, bisphosphonates,
calcitonin, D3 therapy over and above 400 IU orally
daily) 6 months prior to enrolment and during the
study
– History of binge eating or weight gain or loss exceeding
6 kg in past 18 months
– Patients taking any type of coagulation inhibitors (i.e.,
coumadin, heparin, etc.)
Biochemical assays and blood pressure measurements
All biochemical analyses were performed in duplicate. All
baseline measurements were done twice, 1 week apart and
the baseline values reported are the means of these two
measurements. Standard biochemical parameters in blood
and 24-hour urine collections were determined by the hos-
pital department of clinical chemistry using standard, state-
of-the-art methodology as described in reference [22]. All
subjects fasted overnight for 9 am blood draws. In insulin
treated-patients, no insulin was administered after the final
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prescribed dose on the prior day. All oral medications were
withheld until after the fasting blood draw. HbA1c was
determined by means of high performance liquid chro-
matography (HPLC). Homeostasis model assessment in-
sulin resistance (HOMA-IR) was calculated using the pub-
lished HOMA formula [23]. The following endocrine ana-
lyses were made with enzyme-linked immunosorbent as-
says: insulin, proinsulin, C-peptide, intact PTH, C-terminal
FGF-23, plasma renin activity and plasma aldosterone.
25(OH)-D3, 1,25(OH)2-D3 and tetrahydro-aldosterone (ur-
ine) were determined by means of HPLC. Twenty-four-
hour blood pressure readings were recorded using Cardi-
oline® equipment. The equipment was used by an experi-
enced study nurse.
Statistical analysis
Randomisation was unstratified and unblocked. All ana-
lyses are based on the intention-to-treat population, com-
prising all randomised subjects. Intragroup comparisons (to
own group baseline) and intergroup comparison (between
the groups) were carried out using the paired t-test for bio-
chemical data, and results are reported as arithmetic means
and 95% confidence intervals. The Wilcoxon signed rank
test was applied for the analysis of biochemical data that
were not normally distributed (HbA1c and HOMA-IR) and
results are reported as geometric means. The effect of treat-
ment was evaluated by calculating the percentage change
from baseline for all variables studied for all analysis, a
two-tailed p-value <0.05 was considered to indicate stat-
istical significance. For analysis of the potential for differ-
ing treatment effects in patients with and without insulin
treatment, two-way analysis of variance was used. Statist-
ical analysis was performed using SSPS for Windows NT,
version 20.0 (SSPS Inc., Chicago, IL).
Primary endpoint
Change in HbA1c levels at 6 months.
Secondary, exploratory and safety endpoints
Changes in HOMA-IR (calculated as described in referen-
ce [23]) at 3 and 6 months. Changes in calcium/phosphate
metabolism, calci-/phosphotropic hormones. Changes in
proinsulin levels, renin/aldosterone activity/concentration,
24-hour aldosterone excretion rate, 24-hour urinary albu-
min excretion, mean systolic and diastolic 24-hour blood
pressure values, all at 3 and 6 months.
Results
A total of 142 patients with T2DM were recruited between
October and December 2009, 77 were screened and 55 ful-
filled the entry criteria, consented and were enrolled into
the study (n = 29 to D3, n = 26 to the placebo group,
(fig. 1). Baseline characteristics of the study subjects are
summarised in table 1. There were no significant differen-
ces between the two treatment groups at baseline (table 1,
p-values). All of the 55 study participants completed the
study (fig. 1) and there was no change in either antihyper-
glycaemic drugs (insulin requirements) nor in the number
and dose of antihypertensive drugs.
Table 1: Baseline characteristics of the participants, according to the study groups (mean ± standard deviation).
Parameter Vitamin D (D3)
(n = 29)
Placebo
(n = 26)
p-value
Age (y) 66.9 ± 3.1 63.7 ± 3.5 0.367
Gender 10 M (34.5%), 19 F (65.5%) 10 M (38.5%), 16 F (61.5%)
BMI (kg/m²) 28.9 ± 4.3 28.1 ± 3.8 0.169
Current smokers 4 (13.8%) 4 (15.4%)
Ex-smokers 10 (34.5%) 12 (38.5%)
Alcohol, drinks per day 0.7 ± 0.2 1.0 ± 0.3 0.124
Mean SBP (mm Hg)/24h 130.7 ± 14.7 136.3 ± 14.4 0.849
Mean DBP (mm Hg)/24h 82.3 ± 6.0 82.4 ± 11.3 0.912
Duration of diabetes (years) 12.7 ± 1.7 12.6 ± 1.9 0.764
HbA1c (%) 7.0 ± 1.1 7.2 ± 0.9 0.440
Creatinine clearance (ml/min) 101 ± 41 114 ± 46 0.321
Urinary albumin excretion (mg/24h) 200 ± 41 84 ± 21 0.045
25(OH)-D3 (nmol/l) 36.0 ± 18.1 28.1 ± 14.4 0.612
Antihyperglycaemic drugs
Metformin 20 (77%) 23 (79%) 0.698
Sulfonylureas 10 (34%) 4 (15%) 0.047
Pioglitazone 6 (23%) 4 (14%) 0.401
GLP-1 receptor signalling 5 (17%) 1 (4%) 0.041
Insulin 12 (41%) 17 (65%) 0.249
Statins 17 (59%) 15 (58%) 0.812
Antihypertensive drugs
Thiazides 13 (45%) 14 (54%) 0.511
Beta-blockers 11 (38%) 15 (58%) 0.216
ACE-inhibitors 10 (35%) 14 (54%) 0.304
AT-1 receptor antagonists 10 (35%) 14 (54%) 0.231
Calcium channel blockers 8 (28%) 5 (19%) 0.412
ACE = angiotensin converting enzyme; AT = angiotensin; BMI = body mass index; DBP = diastolic blood pressure; GLP-1 = glucagon-like peptide-1; HbA1c = glycosylated
haemoglobin; SBP = systolic blood pressure
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Effect of D3 on HbA1c and HOMA-IR
In both groups and without change in the antihyper-
glycaemic medication regimen, HbA1c increased nonsig-
nificantly when compared to baseline (table 2). However,
HbA1c increased significantly less in patients treated with
D3 than in the placebo group (mean ± standard deviation
+2.9% ± 1.5% vs +6.9% ± 2.1%, p = 0.041, table 2, fig. 2).
There was also a significant treatment effect on HOMA-
IR (table 2 and fig. 2): whereas HOMA-IR decreased by
-12.8% ± 5.6% in the D3 group, it increased by +10% ±
5.4% in the placebo group (p = 0.032). There was no sig-
nificant difference in the serum levels of high-sensitivity
C-reactive protein (hsCRP) as a marker of systemic in-
Figure 1
Study flowchart
Figure 2
Effect of D3 supplementation on the percent changes in HbA1c and
HOMA-IR.
HbA1c = glycosylated haemoglobin; HOMA-IR = homeostasis model
assessment insulin resistance
flammation (table 2) for both the intra- and intergroup com-
parisons. We found no statistically significant interaction of
D3 treatment effect on insulin treatment.
Effect of D3 on calcium/phosphate metabolism and on
calci-/phosphotropic hormones
Administration of D3 significantly suppressed intact PTH
(table 3), had no effect on plasma ionised calcium and
phosphate concentrations (table 4), but significantly in-
creased calciuria in intra- and intergroup comparisons at 3
and 6 months (table 5). In the placebo group, intact PTH
was suppressed significantly at 6 months without signi-
ficant changes in plasma and urinary calcium and phos-
phate concentrations and 24-hour excretion rates. Serum
1,25(OH)2-D3 increased significantly in response to D3, as
did fibroblast growth factor 23 (FGF-23), an osteocyte/
osteoblast-derived phosphaturic hormone, when compared
with baseline values in the D3, but not in the placebo group
(table 3). D3 supplementation significantly increased serum
25(OH)-D3 levels in comparison with baseline and in com-
parison with placebo (table 3). Eleven of the 29 subjects in
the D3 group needed a second injection of 150,000 IU D3
after 3 months. The placebo group also exhibited a signi-
ficant intragroup increase in the serum 25(OH)-D3 concen-
tration from 28 to 62 nmol/l, probably owing to increased
sun exposure in the second part of the study. The serum
25(OH)-D3 concentrations correlated positively and signi-
ficantly with the later termination of the study in the spring/
summer months (data not shown).
Effects of D3 on 24-hour albumin excretion rates and
activity of the renin/aldosterone axis
Twenty-four-hour urinary albumin excretion decreased in
the D3 group from 200 ± 41 mg to 126 ± 39 mg, p = 0.021,
table 5). There was no significant change in plasma act-
ive renin and aldosterone concentrations and in the 24-hour
excretion rates of the tetrahydro metabolite of aldosterone
(table 6).
Effects of D3 on 24-hour ambulatory blood pressure
Twenty-four-hour ambulatory systolic and diastolic blood
pressures decreased significantly within both groups with
no significant intergroup difference (table 7).
Adverse effects
One patient in the placebo group developed a small abscess
at the injection site (after the 3-month injection), which
healed without antibiotics or surgical intervention. No oth-
er side effects were reported.
Discussion
This study examined a population of slightly D3 deficient
(defined as <50 nmol/l [24]), metabolically stable, long-
standing (>10 years) T2DM patients with adequate
baseline blood pressure and acceptable glycaemic control
(HbA1c 7.1% ± 1.0%, table 1). The main findings were:
first, HbA1c showed a differential course during treatment
with D3, with a significantly smaller increase in the treat-
ment group compared with placebo. Second, markers of in-
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sulin resistance were significantly reduced in individuals
treated with D3 compared with placebo.
HOMA-IR has been shown to correlate closely with ana-
lysis of insulin sensitivity by the euglycaemic insulin
clamp method [25]. Based on this calculation, D3 admin-
istration ameliorated insulin resistance and significantly
limited the rise in HbA1c as compared to placebo during
this 6-month intervention trial. The amelioration of insulin
resistance could theoretically be indirect via the reported
anti-inflammatory effects of D3 [26], but this thesis was
not supported by changes in hsCRP levels. However, both
groups exhibited normal baseline hsCRP values, suggest-
ing that systemic inflammatory activity was low and ren-
dering demonstration of a putative inhibitory effect more
difficult. Other studies examining the effects of D3 in pa-
tients at risk for diabetes or normal subjects have failed to
demonstrate a significant effect of the intervention on in-
sulin sensitivity [9–11]. Thus, the effect of D3 may be lim-
ited to establish T2DM and may depend on the degree of
insulin resistance.
Table 2: Effect of vitamin D (D3) supplementation on HBA1c, HOMA-IR, and hsCRP (mean ± standard deviation, 95% confidence interval).
Diabetes parameters and
hsCRP (fasting)
D3 (n = 29) Placebo (n = 26) Treatment
difference
Baseline 3 months 6 months Change (%) Baseline 3 months 6 months Change (%) p-value
Proinsulin (pmol/l) 31.0 ± 29.4
(19.8 to 42.2)
33.4 ± 25.6
(23.7 to 43.1)
32.6 ± 18.9
(25.4 to 39.8)
+5.1 ± 3.9
(+3.6 to 6.6)
49.4 ± 34.8
(35.3 to 63.5)
55.5 ± 31.9
(42.6 to 68.4)
63.8 ± 34.2
(50.0 to 77.6)
+14.1 ± 6.7
(+11.4 to
16.8)
0.342
C-peptide (nmol/l) 1.2 ± 0.8
(0.9 to 1.5)
1.1 ± 0.7
(0.8 to 1.4)
1.2 ± 0.9
(0.9 to 1.5)
0.0 ± 2.3
(–0.9 to 0.9)
0.9 ± 0.8
(0.6 to 1.2)
1.2 ± 0.9
(0.6 to 1.2)
1.1 ± 0.7
(0.8 to 1.4)
+22.0 ± 14
(+16.3 to
27.7)
0.045
Insulin (mU/l) 12.4 ± 9.1
(8.9 to 15.9)
12.5 ± 8.4
(9.3 to 15.7)
11.1 ± 7.6
(8.2 to 14.0)
–11.7 ± 9.6
(–15.4 to 8.1)
11.4 ± 8.9
(7.8 to 15.0)
12.3 ± 7.4
(9.3 to 15.3)
11.4 ± 7.9
(8.2 to 14.6)
0.0 ± 4.1
(–1.7 to 1.7)
0.341
Glucose (mmol/l) 7.8 ± 2.3
(6.9 to 8.7)
7.4 ± 2.4
(6.5 to 8.3)
8.1 ± 2.5
(7.1 to 9.1)
+3.7 ± 4.1
(+2.1 to 5.3)
7.9 ± 2.3
(7.0 to 8.8)
7.7 ± 2.5
(6.7 to 8.7)
8.5 ± 2.6
(7.5 to 9.6)
+7.6 ± 4.7
(+5.7 to 9.5)
0.422
HBA1c (%) 7.0 ± 1.1
(6.6 to 7.4)
7.0 ± 1.0
(6.6 to 7.4)
7.2 ± 1.1
(6.8 to 7.6)
+2.9 ± 1.5
(+2.3 to 3.5)
7.2 ± 0.9
(6.8 to 7.6)
7.4 ± 1.0
(7.0 to 7.8)
7.7 ± 0.9
(7.3 to 8.1)
+6.9 ± 2.1
(+6.1 to 7.7)
0.041
HOMA-IR 4.4 ± 2.4
(3.5 to 5.3)
4.1 ± 2.1
(3.3 to 4.9)
3.9 ± 2.2
(3.1 to 4.7)
–12.8 ± 5.6
(–14.9 to
10.7)
4.0 ± 2.3
(3.1 to 4.9)
4.3 ± 2.1
(3.5 to 5.2)
4.4 ± 2.5
(3.5 to 5.3)
+10 ± 5.4
(+7.8 to12.2)
0.032
hsCRP (mg/l) 1.2 ± 3.1
(0.02 to 2.4)
1.4 ± 2.0
(0.6 to 2.2)
1.5 ± 2.0
(0.7 to 2.3)
+25.1±13.2
(+20.1 to
30.1)
1.5 ± 2.7
(0.4 to 2.6)
1.8 ± 5.4
(–0.4 to 4.0)
1.7 ± 2.0
(0.9 to 2.5)
+13.3 ± 10.1
(+9.2 to 17.4)
0.612
HBA1c = glycosylated haemoglobin; HOMA-IR = homeostasis model assessment insulin resistance; hsCRP = high-sensitivity C-reactive protein
Table 3: Effect of vitamin D (D3) supplementation on calci-/phosphotropic hormones (mean ± standard deviation, 95% confidence interval).
Calci-/phosphotropic
hormones
D3 (n = 29) Placebo (n = 26) Treatment
difference
Baseline 3 months 6 months Change (%) Baseline 3 months 6 months Change (%) p-value
25(OH)-D3 (nmol/l) 36.0 ± 18.1
(29.1 to 42.9)
78.9 ±17.5*“
(72.2 to 85.6)
84.9 ±16.0*
(78.8 to 91.0)
+136 ± 17
(+131 to 144)
28.1 ± 17.4
(21.1 to 35.1)
39.9 ± 18.9
(32.3 to 47.5)
61.7 ± 16.0*
(55.2 to 68.2)
+119 ± 21
(+111 to 128)
0.011
1,25(OH)-D3 (nmol/l) 50 ± 7
(47.3 to 52.7)
n.d. 57 ± 8* #
(54.0 to 60.1)
+14 ± 4
(+13 to 16)
50 ± 9
(46.4 to 53.6)
n.d. 50 ± 8
(46.8 to 53.2)
0 ± 5
(–2 to –2)
0.009
Intact PTH (pmol/l) 5.6 ± 2.5
(4.7 to 6.6)
4.7 ± 2.1*
(3.9 to 5.5)
4.0 ± 2.2*
(3.2 to 4.8)
–29 ± 13
(–34 to –24)
5.5 ± 2.3
(4.6 to 6.4)
5.2 ± 1.9
(4.4 to 6.0)
3.9 ± 1.5
(3.3 to 4.5)
–30 ± 14
(–36 to –24)
0.127
FGF-23 (pg/ml) 38.5 ± 19.3
(31.2 to 45.9)
44.4 ± 18.0*
(37.6 to 51.3)
48.8 ± 18.2*
(41.9 to 55.7)
+27 ± 11
(+23 to 31)
40.0 ± 20.9
(31.6 to 48.4)
36.5 ± 18.2
(29.1 to 43.9)
45.2 ± 19.8
(37.2 to 53.2)
+13 ± 11
(9 to 17)
0.022
FGF-23 = fibroblast growth factor 23; n.d. = not done; PTH = parathyroid hormone
* p <0.05 for intragroup comparison (with own group baseline); # p <0.05 for intergroup comparison (between the groups)
Table 4: Effect of vitamin D (D3) supplementation on plasma electrolytes, urea and creatinine (mean ± standard deviation, 95% confidence interval).
Parameter D3 (n = 29) Placebo (n = 26)
Baseline 3 months 6 months Baseline 3 months 6 months
Na+ (mmol/l) 139 ± 2
(138 to 140)
138 ± 2
(137 to 139)
138 ± 3
(137 to 139)
139 ± 3
(138 to 140)
138 ± 2
(137 to 139)
139 ± 3
(138 to 140)
K+ (mmol/l) 3.8 ± 0.4
(3.7 to 4.0)
3.8 ± 0.5
(3.6 to 4.0)
3.8 ± 0.4
(3.7 to 4.0)
3.8 ± 0.3
(3.7 to 3.9)
3.8 ± 0.5
(3.6 to 4.0)
3.8 ± 0.4
(3.6 to 4.0)
Cl- (mmol/l) 103 ± 3
(102 to 104)
103 ± 2
(102 to 104)
103 ± 3
(102 to 104)
104 ± 4
(102 to 106)
104 ± 2
(103 to 105)
104 ± 3
(103 to 105)
Ion. Ca++ (mmol/l) 1.21 ± 0.05
(1.19 to 1.23)
1.24 ± 0.04
(1.23 to 1.26)
1.22 ± 0.04
(1.21 to 1.24)
1.25 ± 0.05
(1.23 to 1.27)
1.23 ± 0.05
(1.21 to 1.25)
1.18 ± 0.05
(1.16 to 1.20)
PO4 (mmol/l) 1.08 ± 0.12
(1.03 to 1.13)
1.11 ± 0.14
(1.06 to 1.16)
1.14 ± 0.15
(1.08 to 1.20)
1.14 ± 0.13
(1.09 to 1.19)
1.07 ± 0.14
(1.01 to 1.13)
1.14 ± 0.12
(1.09 to 1.19)
Urea (mmol/l) 6.8 ± 2.5
(5.9 to 7.8)
6.9 ± 2.1
(6.1 to 7.7)
7.5 ± 2.6
(6.5 to 8.5)
6.8 ± 2.8
(5.7 to 7.9)
7.0 ± 2.5
(6.0 to 8.0)
6.4 ± 2.7
(5.3 to 7.5)
Creatinine (μmol/l) 72.3 ± 34.6
(59.5 to 85.5)
75.4 ± 38.9
(60.6 to 90.0)
78.2 ± 35.6
(64.7 to 91.8)
68.8 ± 33.8
(55.1 to 82.5)
69.2 ± 31.9
(56.3 to 82.1)
72.6 ± 30.9
(60.1 to 85.1)
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It had been planned to enrol all patients between October
and November to limit the contribution of skin synthesis
of D3 (the recruited subjects all live ~47o N latitude).
However, as a result of patient factors (holidays, profes-
sional engagements, etc.) enrolment could be completed
only at the end of December. The last subjects completed
the protocol in July 2010, thereby natural sun exposure in-
creased D3 in both groups. The effect of D3 administra-
tion may have been mitigated by the fact that the placebo
group exhibited a “spontaneous” increase in 25(OH)-D3
levels most probably owing to increased sun exposure in
the spring and early summer. A small but significant reduc-
tion of C-peptide levels was noted in the D3 arm relative to
placebo. This finding is consistent with the observed tend-
ency to a relative reduction of fasting glucose levels in the
D3 arm and may thus reflect a secondary consequence of
improved insulin sensitivity.
Previously, 1,25(OH)2-D3 has been shown to inhibit renin
gene transcription and vitamin D receptor knockout mice
demonstrate hypertension [27, 28]. However, this study in
T2DM with well-controlled blood pressure did not show
evidence for a detectable inhibitory effect of D3 on the
activity of the renin/aldosterone system on the basis of the
analysis of plasma renin, plasma aldosterone and 24-hour
urinary excretion rates of tetrahydro-aldosterone. Also,
there was no intergroup treatment difference in the 24-hour
ambulatory systolic and diastolic blood pressure measure-
ments.
The observation of a significant decrease in urinary albu-
min excretion in the D3 group is of interest in view of the
association of low D3 status with albuminuria [29] and is
confirmatory evidence for the possible retarding effect of
D3 agonists on progression of glomerular injury [30].
Our study cannot conclusively answer the question as to
whether the observed effects of D3 administration are due
to changes in 25(OH)-D3 or 1,25(OH)2-D3, although the
increase in 1,25(OH)2-D3 was limited to the intervention
group. The increase in 1,25(OH)2-D3 and the decrease in
intact PTH are responsible – at least in part – for the signi-
ficant increase in FGF-23. However, the role of higher cir-
culating levels of 25(OH)-D3 also requires consideration as
osteoblasts exposed to 25(OH)-D3 have been shown to pro-
duce 1,25(OH)2-D3 locally in a paracrine/autocrine fashion
and, thereby, to increase the synthesis of FGF-23 [31].
The D3-induced rise in FGF-23 in this study might be
viewed adversely since injection of pharmacological
amounts of murine FGF-23 into myocardium induced left
ventricular hypertrophy in mice [32], and elevated FGF-23
levels have been reported to be independently associated
with total mortality in a prospective patient cohort with in-
Table 5: Effect of vitamin D (D3) supplementation on 24-hour urinary electrolytes and albumin excretion rates (mean ± standard deviation, 95% confidence interval).
Parameter D3 (n = 29) Placebo (n = 26)
Baseline 3 months 6 months Baseline 3 months 6 months
Na+ (mmol/24h) 206 ± 34
(193 to 219)
170 ± 39
(155 to 185)
191 ± 31
(179 to 203)
177 ± 36
(163 to 192)
172 ± 33
(159 to 185)
184 ± 35
(170 to 198)
K+ (mmol/24h) 73 ± 14
(68 to 78)
76 ± 17
(70 to 83)
96 ± 20
(88 to 104)
63 ± 17
(56 to 70)
68 ± 19
(60 to 76)
75 ± 20
(67 to 83)
Cl- (mmol/24h) 199 ± 29
(188 to 210)
179 ± 27
(169 to 189)
189 ± 31
(177 to 201)
175 ± 29
(163 to 187)
173 ± 32
(160 to 186)
187 ± 27
(176 to 198)
Ca++ (mmol/24h) 3.8 ± 1.1
(3.4 to 4.2)
5.1 ± 1.3*#
(4.6 to 5.6)
5.5 ± 1.0*#
(5.1 to 5.9)
3.3 ± 0.9
(2.9 to 3.7)
3.0 ± 1.2
(2.5 to 3.5)
4.3 ±1.3
(3.8 to 4.8)
PO4 (mmol/24h) 28 ± 5
(26 to 30)
31 ± 6
(29 to 33)
29 ± 5
(27 to 31)
27 ± 6
(25 to 29)
27 ± 7
(24 to 30)
27 ± 5
(25 to 29)
Albumin (mg/24h) 200 ± 41#
(184 to 216)
143 ± 37#
(129 to 157)
126 ± 39*#
(111 to 141)
84 ± 21
(76 to 93)
66 ± 27
(55 to 77)
55 ± 24
(45 to 65)
* p <0.05 for intragroup comparison, # p <0.05 for intergroup comparison (between the groups)
Table 6: Effect of vitamin D (D3) supplementation on renin/aldosterone (mean ± standard deviation, 95% confidence interval).
Renin/aldosterone D3 (n = 29) Placebo (n = 26) Treatment
difference
Baseline 3 months 6 months Change (%) Baseline 3 months 6 months Change (%) p-value
Active plasma renin (mU/l) 12.8 ± 3.1
(11.6 to 14.0)
13.8 ± 2.6
(12.8 to 14.8)
14.0 ± 3.9
(12.6 to 15.5)
+9.4 ± 5.4
(+7.3 to 11.5)
13.1 ± 4.1
(11.4 to 14.8)
12.4 ± 3.4
(11.0 to 13.8)
13.6 ± 3.8
(12.1 to 15.1)
+3.8 ± 4.7
(+1.9 to 5.7)
0.451
Plasma aldosterone (nmol/l) 0.48 ± 0.19
(0.41 to 0.55)
0.44 ± 0.17
(0.38 to 0.51)
0.46 ± 0.16
(0.40 to 0.52)
–4.2 ± 4.2
(–5.8 to –2.6)
0.45 ± 0.15
(0.39 to 0.51)
0.44 ± 0.14
(0.38 to 0.50)
0.41 ± 0.17
(0.34 to 0.48)
–9.9 ± 6.9
(–12.7 to
–7.1)
0.721
Tetrahydro-aldosterone (μg/
24h)
55 ± 10
(51 to 59)
61 ± 11
(57 to 65)
53 ± 9
(50 to 56)
–3.7 ± 7.6
(–6.6 to –0.8)
52 ± 11
(48 to 56)
47 ± 10
(43 to 51)
44 ± 11
(40 to 48)
–15.4 ± 11.2
(–20 to –11)
0.537
Table 7: Effect of vitamin D (D3) supplementation on 24 hour ambulatory blood pressure (mean ± standard deviation, 95% confidence interval).
Parameter D3 (n = 29) Placebo (n = 26)
Baseline 3 months 6 months Baseline 3 months 6 months
Mean systolic BP (mm Hg) 131 ± 3
(130 to 132)
129 ± 3*
(128 to 130)
127 ± 3*
(126 to 128)
135 ± 3
(134 to 136)
133 ± 3
(132 to 134)
128 ± 2*
(127 to 129)
Mean diastolic BP (mm Hg) 83 ± 2
(82 to 84)
76 ± 3*
(75 to 77)
80 ± 2*
(79 to 81)
82 ± 3
(81 to 83)
83 ± 3
(82 to 84)
80 ± 3*
(79 to 81)
BP = blood pressure
* p <0.05 for the intragroup comparison (with own baseline), intergroup comparisons yielded no significant difference
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cident end-stage renal disease [33, 34]. The role of FGF-23
in the incidence of coronary heart disease (CHD) in the
general population is unclear. However, there is substantial
reason to consider that incident CHD is not dependent on
FGF-23 levels in the general population. In a prospective,
nested, case-control cohort study, from the 51,529-subject
Health Professionals Follow-up Study, within the subset
with no history of CHD (mean serum creatinine 1.0 mg/
dl) no association was found between baseline FGF-23
levels and subsequent nonfatal myocardial infarction and
fatal CHD events [35]. Nevertheless, other epidemiological
data have shown that FGF-23 concentration is a risk factor
for increased all-cause and cardiovascular mortality in
Swedish community dwelling adults [36].
Interestingly, it has been demonstrated that insulin-resistant
T2DM patients exhibit an impaired FGF-23 and PTH re-
sponse to an acute phosphate load, sufficient to result in
a supernormal hyperphosphataemic response [37]. Higher
postprandial serum phosphate in T2DM might account, at
least in part, for the systemic vascular calcification ob-
served in this disorder and its status as a cardiovascular risk
factor, as a function of duration of diabetes [38], and thus
it is possible that higher FGF-23 levels might mitigate dia-
betic vascular disease, at least in subjects without chron-
ic kidney disease. Since FGF-23 is produced in osteoblasts
and osteocytes, and osteocyte density is reduced in experi-
mental diabetes [39], it has been suggested that T2DM may
be a state of relative FGF-23 hyporesponsiveness [37]. In
fact, osteoblast-specific deletion of the insulin receptor in
mice results in a phenotype of systemic insulin resistance
and obesity that is mediated in part by osteoblastic endo-
crine dysfunction characterised by diminished secretion of
under-carboxylated osteocalcin [40]. The findings that D3
induced increases in FGF-23 levels in T2DM, as previously
reported in non-diabetics [41], and that D3 can improve
the course of HBA1c and insulin sensitivity of peripheral
tissues (HOMA-IR), raises the possibility that D3 therapy
in T2DM, in addition to improving insulin sensitivity for
glucose homeostasis in muscle cells and hepatocytes, might
also result in increased FGF-23 levels via a similar insulin-
sensitising action in osteocytes/osteoblasts.
The strengths of the present study are the placebo-con-
trolled, prospective study design and the fact that no poten-
tially confounding concomitant medication changes were
made during the observation period. The chief limitation of
this study is the relatively small number of participants and
single centre location. In addition, the “spontaneous” rise
in 25(OH)-D3 levels in the control population may have
narrowed the differences and we cannot assume that the ef-
fects are dependent on different D3 doses. Also, we can-
not exclude an additional effect of clandestine use of D3 in
the placebo group as a result of the subjects’ interest in the
study hypothesis.
Our results encourage the design and conduct of studies
that further explore the roles of D3 and D3 analogues on
glycaemic control in T2DM patients. Future studies should
– among many other points – establish the dose-response
characteristics, examine the best analogue of D3 with re-
gard to the benefit/harm ratio and evaluate the effects in
larger study populations and over longer time periods. In
view of our study results, the effects of D3 on beta-cell
function and insulin secretion merit special attention. In ad-
dition, the relevance of increased FGF-23 on cardiovascu-
lar morbidity should be evaluated in diabetes.
In summary and conclusion, D3 improved insulin sensitiv-
ity (based on HOMA-IR) and affected the course of HbA1c
positively compared to placebo in patients with T2DM, but
did not weaken, and was well tolerated.
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Figures (large format)
Figure 1
Study flowchart
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Figure 2
Effect of D3 supplementation on the percent changes in HbA1c and HOMA-IR.
HbA1c = glycosylated haemoglobin; HOMA-IR = homeostasis model assessment insulin resistance
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